Drug Profile


Alternative Names: B-Lymphocyte stimulator; BAFF; BLyS; TALL-1; THANK; TL 7; TNFSBF 13B; TNSF 20; zTNF 4

Latest Information Update: 25 May 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Human Genome Sciences
  • Developer Dyax Corp.; Human Genome Sciences
  • Class
  • Mechanism of Action B cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Common variable immunodeficiency; Selective immunoglobulin A deficiency

Most Recent Events

  • 31 Dec 2004 Discontinued - Phase-I for Common Variable Immunodeficiency in USA (unspecified route)
  • 31 Dec 2004 Discontinued - Phase-I for Selective immunoglobulin A deficiency in USA (unspecified route)
  • 30 Apr 2004 Suspended - Phase-I for Common Variable Immunodeficiency in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top